TL Antisense Publications

Preclinical and clinical experience of antisense therapy for solid tumors.

Webb MS, Zon G.

Curr Opin Mol Ther. 1999 Aug;1(4):458-63. Review.

Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA).

Roqué F, Mon G, Belardi J, Rodriguez A, Grinfeld L, Long R, Grossman S, Malcolm A, Zon G, Ormont ML, Fischman DL, Shi Y, Zalewski A.

Antisense Nucleic Acid Drug Dev. 2001 Apr;11(2):99-106.

Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide.

Putney SD, Brown J, Cucco C, Lee R, Skorski T, Leonetti C, Geiser T, Calabretta B, Zupi G, Zon G.

Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):451-8.

c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.

Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G.

Cancer Res. 1998 Jan 15;58(2):283-9.

Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.

Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.

Blood. 1996 Aug 1;88(3):1005-12.

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.

Del Bufalo D, Cucco C, Leonetti C, Citro G, D'Agnano I, Benassi M, Geiser T, Zon G, Calabretta B, Zupi G.

Br J Cancer. 1996 Aug;74(3):387-93.

B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1.

Branda RF, Moore AL, Hong R, McCormack JJ, Zon G, Cunningham-Rundles C.

Clin Immunol Immunopathol. 1996 May;79(2):115-21.

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G C, Zupi G.

J Natl Cancer Inst. 1996 Apr 3;88(7):419-29.

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.

Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A.

J Clin Oncol. 1996 Apr;14(4):1320-6.

Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study.

de Serres M, McNulty MJ, Christensen L, Zon G, Findlay JW.

Anal Biochem. 1996 Jan 15;233(2):228-33.

An in vitro messenger RNA binding assay as a tool for identifying hybridization-competent antisense oligonucleotides.

Stull RA, Zon G, Szoka FC Jr.

Antisense Nucleic Acid Drug Dev. 1996 Fall;6(3):221-8.

Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Matsukura M, Koike K, Zon G.

Toxicol Lett. 1995 Dec;82-83:435-8.

Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.

Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B.

J Exp Med. 1995 Dec 1;182(6):1645-53.

Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.

Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, Gallo RC.

J Clin Invest. 1994 Nov;94(5):1736-46.

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L.

Nucleic Acids Res. 1994 Oct 11;22(20):4307-14.

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B.

Proc Natl Acad Sci U S A. 1994 May 10;91(10):4504-8.

Biologic and therapeutic significance of MYB expression in human melanoma.

Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM.

Proc Natl Acad Sci U S A. 1994 May 10;91(10):4499-503.

Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.

Iversen PL, Mata J, Tracewell WG, Zon G.

Antisense Res Dev. 1994 Spring;4(1):43-52.

HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible.

Pirruccello SJ, Perry GA, Bock PJ, Lang MS, Noel SM, Zon G, Iversen PL.

Antisense Res Dev. 1994 Winter;4(4):285-9.

Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

Li G, Lisziewicz J, Sun D, Zon G, Daefler S, Wong-Staal F, Gallo RC, Klotman ME.

J Virol. 1993 Nov;67(11):6882-8.

Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.

Perno CF, Bergamini A, Pesce CD, Milanese G, Capozzi M, Aquaro S, Thaisrivongs S, Tarpley WG, Zon G, D'Agostini C, et al.

J Infect Dis. 1993 Nov;168(5):1148-56.

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts.

Cowsert LM, Fox MC, Zon G, Mirabelli CK.

Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.

In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.

Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823-7.

Comparative inhibition of ras p21 protein synthesis with phosphorus-modified antisense oligonucleotides.

Chang EH, Yu Z, Shinozuka K, Zon G, Wilson WD, Strekowska A.

Anticancer Drug Des. 1989 Oct;4(3):221-32.

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S.

Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.

Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S.

Proc Natl Acad Sci U S A. 1987 Nov;84(21):7706-10.

Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages.

Marcus-Sekura CJ, Woerner AM, Shinozuka K, Zon G, Quinnan GV Jr.

Nucleic Acids Res. 1987 Jul 24;15(14):5749-63.